• 

  Covaxin phase 2 data shows vaccine safe, induces immune response: Lancet Study

  India | March 09, 2021 17:45 IST

  India's first indigenous vaccine against COVID-19, Covaxin, is safe and generates immune response without any serious side effects, according to the interim results of the phase 2 trials published in The Lancet Infectious Diseases journal. 

• 

  No shortage of vaccines in Rajasthan, Centre responds to Gehlot govt

  India | March 09, 2021 16:27 IST

  Reacting to reports that the state may run out of vaccines, the union government clarified on Tuesday that there is no shortage of Covid-19 vaccines in Rajasthan.

• 

  India's COVID-19 vaccination drive gathers pace, nearly 11 lakh doses administered on day 4

  India | March 05, 2021 9:26 IST

  Coronavirus vaccination drive: The next phase of COVID-19 vaccination commenced from March for those above 60 years of age and for people aged 45 and above with specified comorbid conditions.

• 

  Delhi CM Arvind Kejriwal takes first dose of Covid-19 vaccine

  India | March 04, 2021 12:40 IST

  Delhi Chief Minister Arvind Kejriwal on Thursday received the first dose of the Covid-19 vaccine at LNJP hospital.

• 

  COVAXIN shows interim efficacy of 81% in phase 3 clinical trials: Bharat Biotech

  News | March 03, 2021 18:30 IST

  India's indigenously developed vaccine against coronavirus COVAXIN has demonstrated an interim vaccine efficacy of 81 per cent in its Phase 3 clinical trial. The trials involved 25,800 subjects, the largest ever conducted in India, in partnership with ICMR, informed vaccine maker Bharat Biotech.

• 

  COVAXIN shows interim efficacy of 81% in phase 3 clinical trials

  India | March 03, 2021 17:41 IST

  India's indigenously developed vaccine against coronavirus COVAXIN has demonstrated an interim vaccine efficacy of 81 per cent in its Phase 3 clinical trial. The trials involved 25,800 subjects, the largest ever conducted in India, in partnership with ICMR, informed vaccine maker Bharat Biotech.

• 

  Nearly 40 lakh signed up on CoWIN day after PM Modi inoculated

  India | March 02, 2021 16:11 IST

  Vaccines are being provided free of charge at the government health facilities and on a payment basis in the private health facilities. All private hospitals can charge Rs 150 for vaccines and Rs 100 for service charges fixed by the central government.

• 

  Aaj Ki Baat: Why Congress linked Modi’s vaccination with Assam, Kerala, Puducherry polls

  Aaj Ki Baat | March 01, 2021 23:34 IST

  Why Congress linked Modi’s vaccination with Assam, Kerala, Puducherry polls. Opposition questions why Modi opted to take Covaxin jab. Watch this and more on Aaj Ki Baat with Rajat Sharma.

• 

  Sister P Niveda shares her experience of administering COVID vaccine to PM Modi

  News | March 01, 2021 15:00 IST

  Prime Minister Narendra Modi took his first dose of the COVAXIN (Bharat Biotech) at Delhi's AIIMS on March 01 as the second phase of vaccination drive began in India today.

• 

  'Coincidence that PM Modi received Covaxin': Owaisi raises questions over Covishield's efficacy

  India | March 01, 2021 14:11 IST

  Covishield and Covaxin are two anti-coronavirus vaccines approved by the DGCI for emergency use in India. PM Modi received a Covaxin jab.

• 

  Second round of Covid-19 vaccinations begins today| All you need to know

  News | March 01, 2021 11:25 IST

  The government will begin the next phase of the COVID-19 vaccination drive from Monday, March 1. Citizens above 60 years and those aged 45 and above with comorbidities will be able to register and book an appointment on the Co-WIN2.0 portal from 9 am onward on Monday.

Advertisement
• 

  Vaccine registration app Co-WIN to open for registration on Mar 1, walk-ins to likely supersede

  India | February 28, 2021 0:06 IST

  The government is upgrading the CoWIN which was being used in the initial two phases of the vaccination for immunisation of healthcare and frontline workers.

• 

  Covid-19 vaccine at private hospitals likely to cost Rs 300-500. Details

  India | February 27, 2021 17:08 IST

  The NITI Aayog has promulgated a price range of Rs 300-500 for two Covid vaccines that would be available for the priority group at private facilities in the third phase of vaccination set to begin from March 1, sources privy to the development told IANS, adding that the Bharat Biotech's Covaxin would cost a bit higher.

• 

  CSIR-IICT played key role in developing adjuvant for Covaxin, says CSIR

  India | February 27, 2021 6:55 IST

  "The vaccine is formulated with Algel-IMDG, which contains chemisorbed TLR7/8 agonist onto aluminum hydroxide gel to generate the requisite type of immune responses," the CSIR said in a statement.

• 

  Brazil signs deal with Bharat Biotech for 20 million doses of Covaxin

  India | February 26, 2021 9:58 IST

  So far Brazil has vaccinated less than 4 per cent of its population of 210 million people, with some cities stopping immunization campaigns last week due to shortages.

• 

  Vaccine diplomacy: India sent over 3.61 crore anti-coronavirus vaccine doses to 20 countries

  India | February 26, 2021 7:16 IST

  India is one of the world's biggest drugmakers, and an increasing number of countries have already approached it for procuring anti-coronavirus vaccines.

• 

  Free COVID-19 vaccination at government centres for 60+, comorbid people from March 1

  India | February 25, 2021 11:38 IST

  India launched the world's largest vaccination drive on January 16 for the healthcare and frontline workers. According to government data, over 11 lakh people have been administered two doses of Covid vaccines so far.

• 

  Covaxin can be modified to neutralise South African variant in 15 days: Bharat Biotech

  India | February 23, 2021 20:48 IST

  Makers of Covaxin, Bharat Biotech has said that they can modify the vaccine against coronavirus South African variant within 15 days. Bharat Biotech's developed India's own vaccine Covaxin against Covid-19 and was rolled out on January 16.

• 

  Free Covid-19 vaccine for people above 50? Harsh Vardhan decodes govt's plan

  India | February 16, 2021 11:16 IST

  India has approved two vaccines -- Covaxin developed by Bharat Biotech and Covishield from the Oxford/AstraZeneca stable being manufactured by the Serum Institute of India -- for emergency use in the country.

• 

  AIIMS: Covaxin effective for 9-12 months, no serious side-effects so far

  India | February 14, 2021 7:21 IST

  Mathematical calculations indicate that Covaxin may provide immunity against Covid-19 for 9 to 12 months, and there may be a booster shot after this period elapses, Y.K. Gupta, the President of AIIMS Bhopal and Jammu, told IANS.